Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 9004 results

  1. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]

    Awaiting development Reference number: GID-TA11590 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Technology for cancer case finding using primary care records

    Awaiting development Reference number: GID-HTG10176 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  3. Wireless breast lesion localization using Savi Scout seed

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]

    Awaiting development Reference number: GID-TA11948 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Luspatercept for treating anaemia caused by myelofibrosis [ID6697]

    Awaiting development Reference number: GID-TA11915 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]

    Awaiting development Reference number: GID-TA11904 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Awaiting development Reference number: GID-TA11700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    In development Reference number: GID-TA10752 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  11. Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]

    Awaiting development Reference number: GID-TA11473 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development Reference number: GID-TA11428 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

    Technology appraisal guidance
    In development

  14. Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [TSID12390]

    Awaiting development Reference number: GID-TA12008 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids

    Awaiting development Reference number: GID-HTG10171 Expected publication date: TBC

    HealthTech guidance
    Awaiting development